{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"}],"units":"Participants"}],"description":"Will assess the proportion of subjects with partial response or complete response as defined by Response Evaluation Criteria in Solid Tumors version 1.1 response criteria. ORR will be calculated with 95% confidence interval by binomial distribution. The ability of biomarkers to predict ORR will be estimated by chi-square test and/or logistic regression model.","groups":[{"description":"Patients receive pembrolizumab IV over 30 minutes on day 1 and cabozantinib PO QD on days 1-21. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.\n\nCabozantinib: Given PO\n\nPembrolizumab: Given IV","id":"OG000","title":"Treatment (Pembrolizumab, Cabozantinib)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 2 years after treatment start","title":"Overall Response Rate (ORR)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}